Medical News
On April 14, the CDE website announced that HS-10529 tablets, a Class 1 new drug submitted by Hansoh Pharma, have been approved for clinical trials. The drug is intended to treat advanced solid tumors (pancreatic cancer, colorectal cancer, non-small cell lung cancer, etc.) with KRAS G12D mutations.Recently, Zhuhai Beihai Biotechnology Co., Ltd. announced that its independently developed PDC conjugate new drug BH259 has received approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for an Investigational New Drug (IND) application. BH259 is a novel PDC peptide conjugate drug intended for the treatment of solid tumors.On April 14, the clinical trial application for the drug SYS6041 Injection submitted by Jushi Biopharmaceutical Co., Ltd., a holding subsidiary of Xinyao Pharma, has been approved by the U.S. FDA, allowing the initiation of clinical trials for advanced solid tumors in the United States. This drug is a monoclonal antibody conjugate.On April 14, the NMPA website announced that the new drug Pemafibrate Tablets, developed by Kowa Company (Xinghe Pharmaceutical), has been officially approved in China. According to information from Kowa Company's official website, the indication for this approval is for the treatment of dyslipidemia.Investment and Financing in Pharmaceuticals
On April 15, Yuen Bioscience officially listed on the Main Board of the Hong Kong Stock Exchange under the stock code "9606." In this IPO, Yuen Bioscience issued 17,332,300 shares, an increase from its earlier issuance plan. The Hong Kong public offering was subscribed 115.14 times, and the international offering was subscribed 13.52 times. Founded in 2019, Yuen Bioscience is committed to developing innovative Antibody-Drug Conjugates (ADCs) for patients with cancer and autoimmune diseases.Technology-Driven Drug ResearchOn April 9, a latest study published in Nature conducted a genome-wide association study (GWAS) involving nearly 2 million individuals (489,000 cases and 1.472 million controls), identifying 962 independent genetic association signals (513 of which were newly discovered). By integrating single-cell multi-omics, functional validation, and clinical data analysis, the study revealed key pathways and potential drug targets underlying the genetic mechanisms of osteoarthritis.[1]Hatzikotoulas, K., Southam, L., Stefansdottir, L. et al. Translational genomics of osteoarthritis in 1,962,069 individuals. Nature (2025). https://doi.org/10.1038/s41586-025-08771-z
'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)